Table 2 General treatment and PAH targeted therapy in patients with PVOD
From: Targeted therapy in pulmonary veno-occlusive disease: time for a rethink?
Patient number | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
Warfarin | 2.25 mg, po, qod | 2.25 mg, po, qd | No | 5 mg, po, qd | 2 mg, po, qd |
Diuretics | |||||
Spironolactone | No | 20 mg, po, qd | 2No | 20 mg, po, qd | 20 mg, po, qd |
Furosemide | 40 mg, po, qod | No | 20 mg, po, qod | No | 20 mg, po, qod |
Torsemide | 20 mg, po, qod | No | 10 mg, po, qod | No | 10 mg, po, qod |
Digoxin | 0.125 mg, po, qd | No | 0.25 mg, po, qd | No | 0.125 mg, po, qd |
Targeted therapies | |||||
ERAs | No | No | No | No | Ambrisentan, 10 mg, po, qd |
PDE5is | Tadalafil, 10 mg, po, qd | Tadalafil, 10 mg, po, qd | Sildenafil, 20 mg, po, tid | Sildenafil, 20 mg, po, tid | Sildenafil, 20 mg, po, tid |
Prostanoids | Treprostinil, iv, 15.25 ng/kg/min | No | Treprostinil, iv, 17.5 ng/min/kg | No | Iloprost, 1 ml, inh, q3h; Treprostinil, iv, 20 ng/min/kg |